1
白云山
广州白云山医药集团股份有限公司是一家领先的中国跨国医药与健康产品集团，总部位于广东省广州市。2025年，集团年营收总额达776.6亿元人民币（约合108亿美元），位居全球中医药及大健康产业首位。集团业务覆盖医药全价值链，涵盖原料种植、现代提取、消费健康产品及国际贸易，旗下拥有白云山、陈李济（创立于明代）等旗舰品牌。
优势：（1）规模无与伦比，年营收达776.6亿元人民币，为全球中医药…
十大中药品牌排行榜
全球中药与健康产品市场在2026年将逼近2820亿美元，预计到2031年将达到5130亿美元，复合年增长率（CAGR）为7.18%。这一爆发式增长得益于全球人口老龄化、东西方市场对“治未病”预防医学理念的日益重视，以及消费者越来越倾向于选择天然植物药而非合成药物。中药行业正经历一场历史性的范式转变，领先品牌纷纷加速供应链数字化、追求国际监管合规，并跨界拓展至大众消费健康领域。
本排名基于四大核心标准对全球十大中药与健康产品品牌进行评估：全球营收规模（30%），衡量绝对年销售额与市值；品牌影响力与传承（25%），评估品牌知名度、文化意义与历史底蕴；产品创新与研发（25%），评估在循证临床研究、GMP合规生产及新型给药系统方面的投入；以及市场拓展…
前十榜单
2026.07 版本2
云南白药
云南白药集团股份有限公司是中国最具标志性的制药企业之一，以其1902年创制的旗舰产品云南白药止血散而闻名。集团总部位于云南省昆明市，2025年实现年营收411.9亿元人民币，净利润达51.5亿元人民币（同比增长8.51%）。集团已从传统止血应用领域成功拓展至跨品类消费品领域，涵盖口腔护理（云南白药牙膏）、个人护理及功能性健康饮品，仅核心气雾剂产品线就创造了超过25亿元人民币的营收。
优势：（1
3
华润三九
华润三九医药股份有限公司（CR Sanjiu）是一家国有控股的OTC医药巨头，在中国感冒、咳嗽及消化道中成药领域占据无可争议的领先地位。该公司在深圳证券交易所上市（股票代码：000999.SZ），总部位于深圳，2025年实现年营收276.1亿元人民币，净利润同比增长18.05%至33.67亿元人民币，毛利率达行业领先的53.91%。集团运营着标志性的999（三九）品牌，并于2025年被中国工信部认定为卓越级智能工厂，旗下15家制造子公司均已通过ISO 14001…
4
津村株式会社
Tsumura & Co. 是全球技术最先进、质量合规性最高的汉方（日本传统医学）药品制造商，在东京证券交易所上市（股票代码：4540.T）。公司总部位于东京，2025/2026财年实现净销售额1980亿日元（约合人民币95亿元），同比增长9.3%。在日本处方汉方制剂市场占据超过83%的压倒性份额，占日本医药市场总量的8.5%。其四家生产基地（分别位于静冈、茨城、上海和天津）以及位于北海道夕张的专属1000公顷药用植物农场，在全程条码级追溯体系下，每年生产超过2…
品牌
津村株式会社
成立时间
1893
员工规模
4272
覆盖范围
全球（日本、中国、东南亚）
生产基地
日本静冈与茨城；中国上海与天津；北海道夕张药用农场（1000公顷）
总部
日本
市场
东京证券交易所:4540.T
5
北京同仁堂股份有限公司
北京同仁堂股份有限公司是中国历史最悠久、文化底蕴最深厚的医药品牌，始创于1669年清朝康熙年间。该集团在上海证券交易所（600085.SH）和香港交易所（3613.HK）上市，2025年实现营业收入172.6亿元人民币，受宏观经济形势严峻及原材料成本飙升影响，同比下降7.2%。尽管面临短期财务压力，同仁堂在全球仍保持着无与伦比的品牌声望，尤其在急症心血管治疗、镇静安神类药物以及安宫牛黄丸、同仁牛黄清心丸等高端滋补制剂领域。该集团通过香港上市平台及直营中医诊所构建…
品牌
北京同仁堂股份有限公司
成立时间
1669
员工规模
1.7万
覆盖范围
全球（30多个国家，亚洲、北美、欧洲）
生产基地
中国北京；香港（海外分销中心）
总部
中国
市场
上交所:600085.SH, 港交所:3613.HK
6
中国中药控股有限公司
中国中药控股有限公司（China TCM）是全球最大的中药配方颗粒及中药饮片生产商，作为国药集团旗下的核心平台运营。公司于香港联交所上市（股票代码：0570.HK），总部位于广东佛山，2025年实现营业收入147.4亿元人民币，同比下降10.7%，主要因中药配方颗粒被纳入国家集中带量采购（VBP）所致。尽管面临财务压力，中国中药仍拥有全球最广泛的原料采购网络：在全国22个省份布局162个规范化生产基地，覆盖中药材种植面积超过30,600公顷，截至2025年，其1…
7
健合国际控股有限公司
健合集团（H&H国际控股有限公司）是一家总部位于香港和澳大利亚墨尔本的跨国营养与健康集团。该公司在2025年实现营收143亿元人民币（约合22.8亿美元），同比增长10.3%，净利润增长22.7%。其核心品牌Swisse成人营养品在2025年全球年营收突破10亿美元——这距离健合集团收购这一澳大利亚标志性品牌恰好十年。集团在维多利亚州Ravenhall运营着占地17,000平方米的新国家运营中心，配备三条全自动化生产线，年产能达700万瓶营养补充剂…
品牌
健合国际控股有限公司
成立时间
1999
员工规模
2800
覆盖范围
全球（15多个国家：中国、澳大利亚、印度、中东、北美）
生产基地
澳大利亚维多利亚州墨尔本（Ravenhall，17000平方米国家运营中心）
总部
中国
市场
港交所:1112.HK
8
天士力医药集团股份有限公司
天士力医药集团股份有限公司是中国领先的创新型中药企业，专注于心脑血管处方药领域，总部位于天津。该集团在上海证券交易所上市（股票代码：600535.SH），2025年实现总收入82.36亿元人民币，净利润11.04亿元人民币，毛利率高达66.76%。凭借其标志性产品及核心心脏药物管线，天士力处于循证中药与符合FDA标准的现代制药的交汇点。2025年，华润三九完成了对天士力的战略性收购，打造出一家总收入超过350亿元人民币的中药超级航母。天士力拥有强大的研发管线，共…
品牌
天士力医药集团股份有限公司
成立时间
1994
员工规模
8000+
覆盖范围
亚洲、全球（FDA cGMP认证）
生产基地
中国天津（FDA cGMP合规提取与滴丸设施）
总部
中国
市场
上交所:600535.SH
9
汤臣倍健股份有限公司
汤臣倍健股份有限公司是中国维生素与膳食补充剂（VDS）非直销渠道的开拓者及市场领导者，在深圳证券交易所上市（股票代码：300146.SZ），总部位于广东珠海。该公司2025年实现约62.7亿元人民币年营收，面临宏观消费疲软及渠道向直播电商迁移的挑战。其位于珠海的4万平方米透明工厂3.0——耗资4.2亿元人民币建成——配备200余套全球采购的自动化设备、中国首套气动轨道物流系统，年产能达50亿片片剂、30亿粒软胶囊及5亿粒硬胶囊。汤臣倍健是中国首家向公众开放生产设…
品牌
汤臣倍健股份有限公司
成立时间
1995
员工规模
2867
覆盖范围
亚洲（主要在中国，扩展至东南亚）
生产基地
中国广东珠海（透明工厂3.0：40000平方米设施）
总部
中国
市场
深交所:300146.SZ
10
韩国人参公社
韩国人参公社（KT&G）是全球领先的红参及高端滋补保健品企业，总部位于韩国首尔与大田。作为KT&G（韩国烟草与人参）的全资子公司，该公司在韩国交易所上市（股票代码：033780.KS），2025年健康功能食品业务收入达1.137万亿韩元（约合人民币60亿元）。其旗舰品牌正官庄（JUNG KWAN JANG）在韩国国内红参市场占据约80%份额，业务已拓展至全球40多个国家。集团构建了从六年根人参种植、浓缩液提取到零售成品生产的全垂直整合供应链，旗下明星产品包括红参…
常见问题
这些中药品牌是如何排名的？
我们的排名基于数据，而非观点。
本排名采用严格的四维方法论评估全球中医药及保健品品牌。综合品牌评分（0-100分）由以下加权标准计算得出：
1. 全球营收规模（30%）：以最近经审计的财务报告（2025财年）中的年总收入（美元）为依据。营收规模直接反映品牌的市场主导地位、运营韧性以及持续投入研发的能力。营收超过10亿美元的品牌可获得加分。
2. 品牌影响力与传承（25%）：评估品牌在消费者和专业市场的认知深度，包括运营历史年限、在中医药传统中的文化意义以及全球出口布局。成立于1900年之前的传承品牌作为不可替代的文化资产将获得额外权重。
3. 产品创新与研发（25%）：衡量在循证临床研究、符合GMP标准的生产设施、国际监管认证（FDA、PMDA、EMA）以及新型给药系统方面的投入。研发投入超过营收5%的品牌可获得加分。
4. 市场拓展与可持续性（20%）：评估国际收入多元化、供应链可追溯性与ESG实践、B Corp或同等可持续性认证，以及扩大市场覆盖的战略收购或合作。
免责声明：所有财务数据均来自公开的年度报告、证券交易所文件及行业数据库。VerityRank的评分独立进行，不反映付费投放或赞助。排名截至2026年第一季度，并每季度更新。非上市品牌的信息披露可能有限，其评分基于最佳可用估算。
本排名采用严格的四维方法论评估全球中医药及保健品品牌。综合品牌评分（0-100分）由以下加权标准计算得出：
1. 全球营收规模（30%）：以最近经审计的财务报告（2025财年）中的年总收入（美元）为依据。营收规模直接反映品牌的市场主导地位、运营韧性以及持续投入研发的能力。营收超过10亿美元的品牌可获得加分。
2. 品牌影响力与传承（25%）：评估品牌在消费者和专业市场的认知深度，包括运营历史年限、在中医药传统中的文化意义以及全球出口布局。成立于1900年之前的传承品牌作为不可替代的文化资产将获得额外权重。
3. 产品创新与研发（25%）：衡量在循证临床研究、符合GMP标准的生产设施、国际监管认证（FDA、PMDA、EMA）以及新型给药系统方面的投入。研发投入超过营收5%的品牌可获得加分。
4. 市场拓展与可持续性（20%）：评估国际收入多元化、供应链可追溯性与ESG实践、B Corp或同等可持续性认证，以及扩大市场覆盖的战略收购或合作。
免责声明：所有财务数据均来自公开的年度报告、证券交易所文件及行业数据库。VerityRank的评分独立进行，不反映付费投放或赞助。排名截至2026年第一季度，并每季度更新。非上市品牌的信息披露可能有限，其评分基于最佳可用估算。
How Are These Traditional Chinese Medicine Brands Ranked?
Our rankings are built on data, not opinions.
This ranking evaluates global Traditional Chinese Medicine (TCM) and health product brands using a rigorous four-dimensional methodology. The Composite Brand Score (0-100) is calculated from the following weighted criteria:
1. Global Revenue Scale (30%): Annual total revenue in USD, derived from the most recent audited financial reports (FY 2025). Revenue scale directly reflects a brand's market dominance, operational resilience, and ability to fund continuous R&D investment. Brands with revenues exceeding USD 1 billion receive bonus points.
2. Brand Influence and Heritage (25%): Evaluates the depth of brand recognition across consumer and professional markets, including years of operating history, cultural significance in TCM tradition, and global export presence. Heritage brands founded before 1900 receive additional weighting as irreplaceable cultural assets.
3. Product Innovation and R&D (25%): Measures investment in evidence-based clinical research, GMP-compliant manufacturing infrastructure, international regulatory certifications (FDA, PMDA, EMA), and novel drug delivery systems. Brands spending more than 5% of revenue on R&D earn bonus points.
4. Market Expansion and Sustainability (20%): Assesses international revenue diversification, supply chain traceability and ESG practices, B Corp or equivalent sustainability certifications, and strategic acquisitions or partnerships that expand market reach.
Disclaimer: All financial data is sourced from publicly available annual reports, stock exchange filings, and industry databases. VerityRank's scoring is independent and does not reflect paid placements or sponsorships. The ranking is current as of Q1 2026 and is reviewed quarterly. Brands not publicly traded may have limited disclosure, and their scores reflect best available estimates.
This ranking evaluates global Traditional Chinese Medicine (TCM) and health product brands using a rigorous four-dimensional methodology. The Composite Brand Score (0-100) is calculated from the following weighted criteria:
1. Global Revenue Scale (30%): Annual total revenue in USD, derived from the most recent audited financial reports (FY 2025). Revenue scale directly reflects a brand's market dominance, operational resilience, and ability to fund continuous R&D investment. Brands with revenues exceeding USD 1 billion receive bonus points.
2. Brand Influence and Heritage (25%): Evaluates the depth of brand recognition across consumer and professional markets, including years of operating history, cultural significance in TCM tradition, and global export presence. Heritage brands founded before 1900 receive additional weighting as irreplaceable cultural assets.
3. Product Innovation and R&D (25%): Measures investment in evidence-based clinical research, GMP-compliant manufacturing infrastructure, international regulatory certifications (FDA, PMDA, EMA), and novel drug delivery systems. Brands spending more than 5% of revenue on R&D earn bonus points.
4. Market Expansion and Sustainability (20%): Assesses international revenue diversification, supply chain traceability and ESG practices, B Corp or equivalent sustainability certifications, and strategic acquisitions or partnerships that expand market reach.
Disclaimer: All financial data is sourced from publicly available annual reports, stock exchange filings, and industry databases. VerityRank's scoring is independent and does not reflect paid placements or sponsorships. The ranking is current as of Q1 2026 and is reviewed quarterly. Brands not publicly traded may have limited disclosure, and their scores reflect best available estimates.
什么造就了领先的中药品牌？
领先的中医药品牌通过五大核心竞争力维度来区分自己，这些维度创造了持久的竞争护城河。
1. 专有配方库：最有价值的中医药品牌拥有广泛的经典方剂和专利创新专有库。云南白药的止血配方、津村148种处方汉方药以及同仁堂400多种经时间考验的制剂，代表了竞争对手无法复制的不可替代的知识产权。这些配方库通常被列为国家级非物质文化遗产。
2. 垂直供应链控制：顶级中医药公司大力投资后向整合以确保原材料质量。津村在北海道的1000公顷药用草农场每年生产2000多吨，并实现全程条码追溯。中国中药在22个省份拥有162个认证生产基地，构成了几乎无法复制的基础设施壁垒。广州白云山和云南白药同样控制着关键GAP认证的稀有药材种植区，如三七和茯苓。
3. 循证临床验证：现代中医药领导者必须将传统智慧与循证医学相结合。津村在同行评审期刊上发表其汉方产品的严格随机对照试验，符合日本PMDA标准。天士力制药为其心血管药物管线保持FDA-cGMP合规设施。这种临床可信度对于国际市场准入和报销资格至关重要。
4. 跨品类品牌延伸：最成功的中医药品牌已巧妙地从传统治疗类别扩展到消费者健康领域。云南白药进入口腔护理（牙膏）和个人卫生领域，年收入超过25亿元人民币。同仁堂的国潮健康饮品和AI驱动的数字零售转型正在扩大其在Z世代消费者中的基础。健合集团的Swisse品牌在收购十年后实现了10亿美元的收入，展示了跨境品牌组合管理的力量。
5. 制造智能与透明度：汤臣倍健在珠海的“透明工厂3.0”已接待超过200万公众参观，成为强大的消费者信任建设者。津村位于静冈和茨城的自动化提取设施代表了世界上最先进的汉方药制造基础设施。这些在制造透明度和质量可审计性方面的投资正在设定新的行业标准，并推动整个行业的监管合规。
1. 专有配方库：最有价值的中医药品牌拥有广泛的经典方剂和专利创新专有库。云南白药的止血配方、津村148种处方汉方药以及同仁堂400多种经时间考验的制剂，代表了竞争对手无法复制的不可替代的知识产权。这些配方库通常被列为国家级非物质文化遗产。
2. 垂直供应链控制：顶级中医药公司大力投资后向整合以确保原材料质量。津村在北海道的1000公顷药用草农场每年生产2000多吨，并实现全程条码追溯。中国中药在22个省份拥有162个认证生产基地，构成了几乎无法复制的基础设施壁垒。广州白云山和云南白药同样控制着关键GAP认证的稀有药材种植区，如三七和茯苓。
3. 循证临床验证：现代中医药领导者必须将传统智慧与循证医学相结合。津村在同行评审期刊上发表其汉方产品的严格随机对照试验，符合日本PMDA标准。天士力制药为其心血管药物管线保持FDA-cGMP合规设施。这种临床可信度对于国际市场准入和报销资格至关重要。
4. 跨品类品牌延伸：最成功的中医药品牌已巧妙地从传统治疗类别扩展到消费者健康领域。云南白药进入口腔护理（牙膏）和个人卫生领域，年收入超过25亿元人民币。同仁堂的国潮健康饮品和AI驱动的数字零售转型正在扩大其在Z世代消费者中的基础。健合集团的Swisse品牌在收购十年后实现了10亿美元的收入，展示了跨境品牌组合管理的力量。
5. 制造智能与透明度：汤臣倍健在珠海的“透明工厂3.0”已接待超过200万公众参观，成为强大的消费者信任建设者。津村位于静冈和茨城的自动化提取设施代表了世界上最先进的汉方药制造基础设施。这些在制造透明度和质量可审计性方面的投资正在设定新的行业标准，并推动整个行业的监管合规。
What Makes a Leading Traditional Chinese Medicine Brand?
Leading TCM brands distinguish themselves through fivecore competitive capabilities dimensions that create durable competitive moats.
1. Proprietary Formulation Libraries: The most valuable TCM brands maintain extensive proprietary libraries of classical formulas (classic formulations) and patented innovations. Yunnan Baiyao's hemostatic formulations, Tsumura's 148 prescription Kampo formulas, and Tong Ren Tang's 400+ time-tested preparations represent irreplaceable intellectual property that cannot be replicated by competitors. These libraries are often protected as National Intangible Cultural Heritage assets.
2. Vertical Supply Chain Control: Top TCM companies have invested heavily in backward integration to ensure raw material quality. Tsumura's 1,000-hectare Hokkaido medicinal herb farm produces 2,000+ tons annually under full barcode traceability. China TCM's 162 certified production bases covering 22 provinces represent a near-impossible-to-replicate infrastructure barrier. Guangzhou Baiyunshan and Yunnan Baiyao similarly control keyGAP-certified cultivation zones for rare ingredients like Panax notoginseng and Poria cocos.
3. Evidence-Based Clinical Validation: The modern TCM leader must bridge traditional wisdom with evidence-based medicine. Tsumura publishes rigorous randomized controlled trials (RCTs) on its Kampo products in peer-reviewed journals, meeting Japanese PMDA standards. Tasly Pharmaceutical maintains FDA-cGMP compliant facilities for its cardiovascular drug pipeline. This clinical credibility is essential for international market entry and reimbursement eligibility.
4. Cross-Category Brand Extensions: The most successful TCM brands have masterfully extended from traditional therapeutic categories into consumer wellness. Yunnan Baiyao's entry into oral care (toothpaste) and personal hygiene generates over CNY 2.5 billion in annual revenue. Tong Ren Tang's national-chic health beverages and AI-empowered digital retail transformation are expanding its consumer base among Gen-Z shoppers. H&H Group's Swisse brand achieved USD 1 billion in revenue a decade after acquisition, demonstrating the power of cross-border brand portfolio management.
5. Manufacturing Intelligence and Transparency: By-health's "Transparent Factory 3.0" in Zhuhai—receiving over 2 million public visitors—has become a powerful consumer trust builder. Tsumura's automated extraction facilities in Shizuoka and Ibaraki represent the world's most advanced Kampo manufacturing infrastructure. These investments in manufacturing transparency and quality auditability are setting new industry standards and driving regulatory compliance across the sector.
1. Proprietary Formulation Libraries: The most valuable TCM brands maintain extensive proprietary libraries of classical formulas (classic formulations) and patented innovations. Yunnan Baiyao's hemostatic formulations, Tsumura's 148 prescription Kampo formulas, and Tong Ren Tang's 400+ time-tested preparations represent irreplaceable intellectual property that cannot be replicated by competitors. These libraries are often protected as National Intangible Cultural Heritage assets.
2. Vertical Supply Chain Control: Top TCM companies have invested heavily in backward integration to ensure raw material quality. Tsumura's 1,000-hectare Hokkaido medicinal herb farm produces 2,000+ tons annually under full barcode traceability. China TCM's 162 certified production bases covering 22 provinces represent a near-impossible-to-replicate infrastructure barrier. Guangzhou Baiyunshan and Yunnan Baiyao similarly control keyGAP-certified cultivation zones for rare ingredients like Panax notoginseng and Poria cocos.
3. Evidence-Based Clinical Validation: The modern TCM leader must bridge traditional wisdom with evidence-based medicine. Tsumura publishes rigorous randomized controlled trials (RCTs) on its Kampo products in peer-reviewed journals, meeting Japanese PMDA standards. Tasly Pharmaceutical maintains FDA-cGMP compliant facilities for its cardiovascular drug pipeline. This clinical credibility is essential for international market entry and reimbursement eligibility.
4. Cross-Category Brand Extensions: The most successful TCM brands have masterfully extended from traditional therapeutic categories into consumer wellness. Yunnan Baiyao's entry into oral care (toothpaste) and personal hygiene generates over CNY 2.5 billion in annual revenue. Tong Ren Tang's national-chic health beverages and AI-empowered digital retail transformation are expanding its consumer base among Gen-Z shoppers. H&H Group's Swisse brand achieved USD 1 billion in revenue a decade after acquisition, demonstrating the power of cross-border brand portfolio management.
5. Manufacturing Intelligence and Transparency: By-health's "Transparent Factory 3.0" in Zhuhai—receiving over 2 million public visitors—has become a powerful consumer trust builder. Tsumura's automated extraction facilities in Shizuoka and Ibaraki represent the world's most advanced Kampo manufacturing infrastructure. These investments in manufacturing transparency and quality auditability are setting new industry standards and driving regulatory compliance across the sector.
2025-2026年中药市场如何变化？
全球中医药与健康市场在2026年价值2820亿美元，正在经历四个变革性的结构性转变，这些转变将重塑到2030年的竞争动态。
市场规模与增长：全球中医药市场预计将从2026年的2820亿美元增长到2031年的5130亿美元（复合年增长率：7.18%）。仅中国国内中医药市场在2025年就达到962亿欧元，随着西方消费者接受预防医学和植物性健康解决方案，国际市场占比日益显著。COVID-19大流行是一个意外的催化剂，加速了全球对免疫支持传统疗法的认识。
趋势一：智能制造革命：领先的中医药公司正在部署工业4.0技术，以解决历史性的质量不一致问题。津村（Tsumura）的条码级农场到工厂追溯系统、中国中药（China TCM）基于区块链的109种核心草药中95种的质量监控，以及汤臣倍健（By-health）的气动轨道物流系统，代表了新的制造标准。到2027年，中国中医药行业的智能工厂渗透率预计将超过40%，而2022年这一比例不到15%。
趋势二：带量采购（VBP）重组：中国的国家带量采购计划已压缩了西药价格，现在正影响中药配方颗粒和处方中药产品。中国中药控股（China TCM Holdings）因VBP规定的降价，在2025年收入下降10.7%并出现净亏损。这一政策正在推动整合——没有成本优势的小型制造商正在退出市场——而资本雄厚的参与者如华润三九（CR Sanjiu）和国药集团（Sinopharm）正在通过并购获取市场份额。
趋势三：东西方战略融合：跨境并购正在加速，中国和日本的中医药公司寻求将东方草药专业知识与西方营养科学和品牌管理相结合。健合集团（H&H Group）成功收购Swisse（2025年收入达10亿美元里程碑）以及日本三井（Mitsui）和乐敦（Rohto）收购新加坡余仁生（Eu Yan Sang）（约6亿美元）展示了持续的整合。这种融合正在创造跨太平洋的健康巨头，其合并收入达数十亿美元。
趋势四：预防医学与生活方式整合：“治未病”理念正推动中医药公司进入消费者健康和生活方式领域。从云南白药（Yunnan Baiyao）的功能性饮料产品组合，到同仁堂（Tong Ren Tang）的健康咖啡馆概念店，再到韩国人参公社（Korea Ginseng Corporation）的高端化战略，该行业正从疾病治疗转向日常健康整合。这一结构性转变正在将总可寻址市场（TAM）从传统患者群体扩展到全球25-55岁的健康意识消费者。
市场规模与增长：全球中医药市场预计将从2026年的2820亿美元增长到2031年的5130亿美元（复合年增长率：7.18%）。仅中国国内中医药市场在2025年就达到962亿欧元，随着西方消费者接受预防医学和植物性健康解决方案，国际市场占比日益显著。COVID-19大流行是一个意外的催化剂，加速了全球对免疫支持传统疗法的认识。
趋势一：智能制造革命：领先的中医药公司正在部署工业4.0技术，以解决历史性的质量不一致问题。津村（Tsumura）的条码级农场到工厂追溯系统、中国中药（China TCM）基于区块链的109种核心草药中95种的质量监控，以及汤臣倍健（By-health）的气动轨道物流系统，代表了新的制造标准。到2027年，中国中医药行业的智能工厂渗透率预计将超过40%，而2022年这一比例不到15%。
趋势二：带量采购（VBP）重组：中国的国家带量采购计划已压缩了西药价格，现在正影响中药配方颗粒和处方中药产品。中国中药控股（China TCM Holdings）因VBP规定的降价，在2025年收入下降10.7%并出现净亏损。这一政策正在推动整合——没有成本优势的小型制造商正在退出市场——而资本雄厚的参与者如华润三九（CR Sanjiu）和国药集团（Sinopharm）正在通过并购获取市场份额。
趋势三：东西方战略融合：跨境并购正在加速，中国和日本的中医药公司寻求将东方草药专业知识与西方营养科学和品牌管理相结合。健合集团（H&H Group）成功收购Swisse（2025年收入达10亿美元里程碑）以及日本三井（Mitsui）和乐敦（Rohto）收购新加坡余仁生（Eu Yan Sang）（约6亿美元）展示了持续的整合。这种融合正在创造跨太平洋的健康巨头，其合并收入达数十亿美元。
趋势四：预防医学与生活方式整合：“治未病”理念正推动中医药公司进入消费者健康和生活方式领域。从云南白药（Yunnan Baiyao）的功能性饮料产品组合，到同仁堂（Tong Ren Tang）的健康咖啡馆概念店，再到韩国人参公社（Korea Ginseng Corporation）的高端化战略，该行业正从疾病治疗转向日常健康整合。这一结构性转变正在将总可寻址市场（TAM）从传统患者群体扩展到全球25-55岁的健康意识消费者。
How Is the Traditional Chinese Medicine Market Changing in 2025-2026?
The global TCM and wellness market, valued at USD 282 billion in 2026, is undergoing four transformative structural shifts that will reshape competitive dynamics through 2030.
Market Scale and Growth: The global TCM market is projected to grow from USD 282 billion in 2026 to USD 513 billion by 2031 (CAGR: 7.18%). China's domestic TCM market alone reached EUR 96.2 billion in 2025, with international markets accounting for an increasingly significant share as Western consumers embrace preventive medicine and plant-based health solutions. The COVID-19 pandemic served as an unexpected catalyst, accelerating global awareness of immune-supportive traditional remedies.
Trend 1: Intelligent Manufacturing Revolution: Leading TCM companies are deploying Industry 4.0 technologies to solve the historic quality inconsistency problem. Tsumura's barcode-level farm-to-factory traceability system, China TCM's blockchain-based quality monitoring for 95 of 109 core herbs, and By-health's pneumatic rail logistics system represent the new manufacturing standard. By 2027, smart factory penetration in China's TCM sector is expected to exceed 40%, compared to less than 15% in 2022.
Trend 2: Volume-Based Procurement (VBP) Restructuring: China's national VBP scheme, which has already compressed prices for Western pharmaceuticals, is now impacting TCM formula granules and prescription TCM products. China TCM Holdings experienced a 10.7% revenue decline and net loss in 2025 due to VBP-mandated price reductions. This policy is forcing consolidation—smaller manufacturers without cost advantages are exiting the market—while well-capitalized players like CR Sanjiu and Sinopharm are acquiring market share through M&A.
Trend 3: East-West Strategic Convergence: Cross-border M&A is accelerating as Chinese and Japanese TCM companies seek to combine Eastern herbal expertise with Western nutritional science and brand management. H&H Group's successful Swisse acquisition (USD 1 billion revenue milestone in 2025) and Japan-based Mitsui and Rohto's acquisition of Singapore's Eu Yan Sang (~$600 million) demonstrate the ongoing consolidation. This convergence is creating transpacific wellness giants with multi-billion dollar combined revenues.
Trend 4: Preventive Medicine and Lifestyle Integration: The "zhi wei bing" (preventive medicine) philosophy is driving TCM companies toward consumer health and lifestyle categories. From Yunnan Baiyao's functional beverage portfolio to Tong Ren Tang's health café concept stores and Korea Ginseng Corporation's premiumization strategy, the industry is shifting from disease treatment to daily wellness integration. This structural transition is expanding TAM (Total Addressable Market) beyond traditional patient populations to include health-conscious consumers aged 25-55 globally.
Market Scale and Growth: The global TCM market is projected to grow from USD 282 billion in 2026 to USD 513 billion by 2031 (CAGR: 7.18%). China's domestic TCM market alone reached EUR 96.2 billion in 2025, with international markets accounting for an increasingly significant share as Western consumers embrace preventive medicine and plant-based health solutions. The COVID-19 pandemic served as an unexpected catalyst, accelerating global awareness of immune-supportive traditional remedies.
Trend 1: Intelligent Manufacturing Revolution: Leading TCM companies are deploying Industry 4.0 technologies to solve the historic quality inconsistency problem. Tsumura's barcode-level farm-to-factory traceability system, China TCM's blockchain-based quality monitoring for 95 of 109 core herbs, and By-health's pneumatic rail logistics system represent the new manufacturing standard. By 2027, smart factory penetration in China's TCM sector is expected to exceed 40%, compared to less than 15% in 2022.
Trend 2: Volume-Based Procurement (VBP) Restructuring: China's national VBP scheme, which has already compressed prices for Western pharmaceuticals, is now impacting TCM formula granules and prescription TCM products. China TCM Holdings experienced a 10.7% revenue decline and net loss in 2025 due to VBP-mandated price reductions. This policy is forcing consolidation—smaller manufacturers without cost advantages are exiting the market—while well-capitalized players like CR Sanjiu and Sinopharm are acquiring market share through M&A.
Trend 3: East-West Strategic Convergence: Cross-border M&A is accelerating as Chinese and Japanese TCM companies seek to combine Eastern herbal expertise with Western nutritional science and brand management. H&H Group's successful Swisse acquisition (USD 1 billion revenue milestone in 2025) and Japan-based Mitsui and Rohto's acquisition of Singapore's Eu Yan Sang (~$600 million) demonstrate the ongoing consolidation. This convergence is creating transpacific wellness giants with multi-billion dollar combined revenues.
Trend 4: Preventive Medicine and Lifestyle Integration: The "zhi wei bing" (preventive medicine) philosophy is driving TCM companies toward consumer health and lifestyle categories. From Yunnan Baiyao's functional beverage portfolio to Tong Ren Tang's health café concept stores and Korea Ginseng Corporation's premiumization strategy, the industry is shifting from disease treatment to daily wellness integration. This structural transition is expanding TAM (Total Addressable Market) beyond traditional patient populations to include health-conscious consumers aged 25-55 globally.
买家在选择中药产品时应考虑什么？
买家——从个人消费者到医疗机构——应根据五个关键选择标准评估中药和保健品，这些标准有具体技术参数和监管标准支持。
因素1：监管批准和GMP认证： 始终验证制造商是否持有相关国家机构颁发的有效GMP（良好生产规范）认证。在中国，CFDA（国家食品药品监督管理总局）认证是强制性的；在日本，处方汉方药需要PMDA（药品和医疗器械管理局）批准；在美国，任何声称具有治疗作用的中药产品必须符合FDA膳食补充剂法规（21 CFR 111）。津村的所有处方汉方药均持有日本PMDA批准——消费者应拒绝任何没有可验证监管文件的产品。
因素2：原材料来源和可追溯性： 要求制造商披露原材料采购信息。最高质量的中药产品会注明地理来源（例如，“云南省GAP认证种植基地”）以及农药、重金属和黄曲霉毒素的检测标准。中国中药覆盖95种药材的在线追溯系统和津村1000公顷的北海道农场代表了行业领先的透明度。避免没有批次检测证书（COA——分析证书）的产品。
因素3：活性成分标准化： 信誉良好的中药制造商投资于活性标志物化合物的标准化——这些可测量的成分驱动治疗效果。例如，津村将其汉方颗粒标准化为特定浓度的小檗碱、芍药苷和甘草酸。汤臣倍健在其补充剂中公布了每种成分的精确植物来源和活性化合物含量。没有标准化活性成分规格的产品可能表现出显著的批次间效力差异。
因素4：临床证据和安全性概况： 评估产品是否经过严格的临床评估。津村为其汉方制剂发布了随机对照试验数据；天士力为其心血管管线维护了符合FDA-cGMP标准的设施；云南白药在同行评审期刊上发表了其止血产品的临床数据。对没有支持性临床证据而声称具有治疗作用的产品保持谨慎。中药品牌的网站应提供同行评审出版物的参考文献。
因素5：储存、保质期和包装： 中药产品——尤其是颗粒剂、饮片和液体制剂——对温度、湿度和光线敏感。验证产品包装是否包含足够的保护（防紫外线瓶、干燥剂包），并且保质期是否清晰标注。进口产品应标明运输过程中适当的冷链或低温储存。信誉良好的品牌提供批次追踪码，使消费者能够验证生产日期和质量检验结果。
因素1：监管批准和GMP认证： 始终验证制造商是否持有相关国家机构颁发的有效GMP（良好生产规范）认证。在中国，CFDA（国家食品药品监督管理总局）认证是强制性的；在日本，处方汉方药需要PMDA（药品和医疗器械管理局）批准；在美国，任何声称具有治疗作用的中药产品必须符合FDA膳食补充剂法规（21 CFR 111）。津村的所有处方汉方药均持有日本PMDA批准——消费者应拒绝任何没有可验证监管文件的产品。
因素2：原材料来源和可追溯性： 要求制造商披露原材料采购信息。最高质量的中药产品会注明地理来源（例如，“云南省GAP认证种植基地”）以及农药、重金属和黄曲霉毒素的检测标准。中国中药覆盖95种药材的在线追溯系统和津村1000公顷的北海道农场代表了行业领先的透明度。避免没有批次检测证书（COA——分析证书）的产品。
因素3：活性成分标准化： 信誉良好的中药制造商投资于活性标志物化合物的标准化——这些可测量的成分驱动治疗效果。例如，津村将其汉方颗粒标准化为特定浓度的小檗碱、芍药苷和甘草酸。汤臣倍健在其补充剂中公布了每种成分的精确植物来源和活性化合物含量。没有标准化活性成分规格的产品可能表现出显著的批次间效力差异。
因素4：临床证据和安全性概况： 评估产品是否经过严格的临床评估。津村为其汉方制剂发布了随机对照试验数据；天士力为其心血管管线维护了符合FDA-cGMP标准的设施；云南白药在同行评审期刊上发表了其止血产品的临床数据。对没有支持性临床证据而声称具有治疗作用的产品保持谨慎。中药品牌的网站应提供同行评审出版物的参考文献。
因素5：储存、保质期和包装： 中药产品——尤其是颗粒剂、饮片和液体制剂——对温度、湿度和光线敏感。验证产品包装是否包含足够的保护（防紫外线瓶、干燥剂包），并且保质期是否清晰标注。进口产品应标明运输过程中适当的冷链或低温储存。信誉良好的品牌提供批次追踪码，使消费者能够验证生产日期和质量检验结果。
What Should Buyers Consider When Selecting Traditional Chinese Medicine Products?
Buyers—from individual consumers to healthcare institutions—should evaluate TCM and health products across five critical selection criteria backed by specific technical parameters and regulatory standards.
Factor 1: Regulatory Approval andGMP Certification: Always verify that the manufacturer holds valid GMP (Good Manufacturing Practice) certification from the relevant national authority. In China, CFDA (China Food and Drug Administration) certification is mandatory; in Japan, PMDA (Pharmaceuticals and Medical Devices Agency) approval is required for prescription Kampo; in the US, any TCM product making therapeutic claims must comply with FDA dietary supplement regulations (21 CFR 111). Tsumura holds Japanese PMDA approval for all its prescription Kampo products—consumers should reject any product without verifiable regulatory documentation.
Factor 2: Raw Material Origin and Traceability: Request the manufacturer's raw material sourcing disclosure. The highest-quality TCM products specify the geographic origin (e.g., "GAP-certified cultivation base in Yunnan Province") and testing standards for pesticides, heavy metals, and aflatoxin. China TCM's online traceability system covering 95 herbs and Tsumura's 1,000-hectare Hokkaido farm represent industry-leading transparency. Avoid products without batch-level testing certificates (COA - Certificate of Analysis).
Factor 3: Standardization of Active Ingredients: Reputable TCM manufacturers invest in the standardization of active marker compounds—the measurable constituents that drive therapeutic efficacy. For example, Tsumura standardizes its Kampo granules to specific concentrations of berberine, paeoniflorin, and glycyrrhizin. By-health publishes the exact botanical origin and active compound content for each ingredient in its supplements. Products without standardized active ingredient specifications may exhibit significant batch-to-batch potency variation.
Factor 4: Clinical Evidence and Safety Profile: Evaluate whether the product has been subject to rigorous clinical evaluation. Tsumura publishes RCT data for its Kampo formulations; Tasly Pharmaceutical maintains FDA-cGMP compliant facilities for its cardiovascular pipeline; Yunnan Baiyao has published clinical data on its hemostatic products in peer-reviewed journals. Be cautious of products making therapeutic claims without any supporting clinical evidence. The TCM brand's website should provide references to peer-reviewed publications.
Factor 5: Storage, Shelf Life, and Packaging: TCM products—especially granules, decoction pieces, and liquid preparations—are sensitive to temperature, humidity, and light. Verify that the product packaging includes adequate protection (UV-blocking bottles, desiccant pouches) and that the shelf life is clearly labeled. Imported products should indicate proper cold-chain or cool-temperature storage during transit. Reputable brands provide batch tracking codes that allow consumers to verify manufacturing date and quality inspection results.
Factor 1: Regulatory Approval andGMP Certification: Always verify that the manufacturer holds valid GMP (Good Manufacturing Practice) certification from the relevant national authority. In China, CFDA (China Food and Drug Administration) certification is mandatory; in Japan, PMDA (Pharmaceuticals and Medical Devices Agency) approval is required for prescription Kampo; in the US, any TCM product making therapeutic claims must comply with FDA dietary supplement regulations (21 CFR 111). Tsumura holds Japanese PMDA approval for all its prescription Kampo products—consumers should reject any product without verifiable regulatory documentation.
Factor 2: Raw Material Origin and Traceability: Request the manufacturer's raw material sourcing disclosure. The highest-quality TCM products specify the geographic origin (e.g., "GAP-certified cultivation base in Yunnan Province") and testing standards for pesticides, heavy metals, and aflatoxin. China TCM's online traceability system covering 95 herbs and Tsumura's 1,000-hectare Hokkaido farm represent industry-leading transparency. Avoid products without batch-level testing certificates (COA - Certificate of Analysis).
Factor 3: Standardization of Active Ingredients: Reputable TCM manufacturers invest in the standardization of active marker compounds—the measurable constituents that drive therapeutic efficacy. For example, Tsumura standardizes its Kampo granules to specific concentrations of berberine, paeoniflorin, and glycyrrhizin. By-health publishes the exact botanical origin and active compound content for each ingredient in its supplements. Products without standardized active ingredient specifications may exhibit significant batch-to-batch potency variation.
Factor 4: Clinical Evidence and Safety Profile: Evaluate whether the product has been subject to rigorous clinical evaluation. Tsumura publishes RCT data for its Kampo formulations; Tasly Pharmaceutical maintains FDA-cGMP compliant facilities for its cardiovascular pipeline; Yunnan Baiyao has published clinical data on its hemostatic products in peer-reviewed journals. Be cautious of products making therapeutic claims without any supporting clinical evidence. The TCM brand's website should provide references to peer-reviewed publications.
Factor 5: Storage, Shelf Life, and Packaging: TCM products—especially granules, decoction pieces, and liquid preparations—are sensitive to temperature, humidity, and light. Verify that the product packaging includes adequate protection (UV-blocking bottles, desiccant pouches) and that the shelf life is clearly labeled. Imported products should indicate proper cold-chain or cool-temperature storage during transit. Reputable brands provide batch tracking codes that allow consumers to verify manufacturing date and quality inspection results.
哪些中药品牌在可持续发展方面领先？
三个中药和健康品牌正在传统医药领域树立环境和社会治理的全球标准，其可衡量的成果使其成为ESG领导者。
1. 健合集团（H&H Group）/ Swisse（ESG评分：94/100）：健合集团于2025年获得B Corp认证——这是环境和社会绩效最严格的全球标准——使其成为首家获得此殊荣的大型中药/健康公司。该集团位于维多利亚州Ravenhall的新国家运营中心占地17,000平方米，配备433千瓦太阳能阵列和雨水回收系统，预计每年减少380吨二氧化碳当量的碳排放。Swisse的原料采购政策要求使用RSPO认证的棕榈油衍生物，并禁止在所有配方中使用微塑料。健合的可持续发展报告由Anthesis Group进行第三方验证，为全球健康行业树立了新的透明度基准。
2. 津村株式会社（Tsumura and Co.）（ESG评分：91/100）：津村运营着全球最可持续的药草供应链。其位于北海道的1,000公顷专属农场采用综合虫害管理（IPM）和精准农业技术，自2018年以来农药使用量减少了40%。该公司在日本的四家制造工厂（静冈、茨城、上海、天津）全部使用100%可再生电力，所有设施均获得ISO 14001环境管理体系认证。津村的条码级可追溯系统——从种子选择到成品颗粒——树立了制药供应链透明度的全球标准，该公司已承诺到2040年实现净零碳排放。
3. 华润三九（CR Sanjiu）（ESG评分：88/100）：华润三九建立了中国制药行业最全面的ESG项目之一，旗下15家制造子公司获得ISO 14001环境管理体系认证，每年进行超过600次EHS（环境、健康和安全）演练。该集团获得中国工信部卓越级智能工厂称号，不仅反映了生产效率，也体现了可衡量的环境绩效：自2022年以来，单位产出能耗优化了22%，主要生产基地的废水回收率超过85%。华润三九2025年收购天士力医药，预计将通过联合可持续发展基础设施投资创造显著的ESG协同效应。
新兴领导者：韩国人参公社（KGC）（ESG评分：82/100）：KGC在韩国垂直整合的六年生人参种植项目采用专有土壤管理技术，允许在同一土地上重复种植——减少了土地使用扩张压力。该公司位于大田的专用研发中心正在为其消费健康产品开发可生物降解包装，目标是到2028年实现60%的可回收率。KGC支持韩国农村参农的社区投资计划代表了重要的社会可持续性维度，使其与纯粹追求利润的竞争对手区分开来。
1. 健合集团（H&H Group）/ Swisse（ESG评分：94/100）：健合集团于2025年获得B Corp认证——这是环境和社会绩效最严格的全球标准——使其成为首家获得此殊荣的大型中药/健康公司。该集团位于维多利亚州Ravenhall的新国家运营中心占地17,000平方米，配备433千瓦太阳能阵列和雨水回收系统，预计每年减少380吨二氧化碳当量的碳排放。Swisse的原料采购政策要求使用RSPO认证的棕榈油衍生物，并禁止在所有配方中使用微塑料。健合的可持续发展报告由Anthesis Group进行第三方验证，为全球健康行业树立了新的透明度基准。
2. 津村株式会社（Tsumura and Co.）（ESG评分：91/100）：津村运营着全球最可持续的药草供应链。其位于北海道的1,000公顷专属农场采用综合虫害管理（IPM）和精准农业技术，自2018年以来农药使用量减少了40%。该公司在日本的四家制造工厂（静冈、茨城、上海、天津）全部使用100%可再生电力，所有设施均获得ISO 14001环境管理体系认证。津村的条码级可追溯系统——从种子选择到成品颗粒——树立了制药供应链透明度的全球标准，该公司已承诺到2040年实现净零碳排放。
3. 华润三九（CR Sanjiu）（ESG评分：88/100）：华润三九建立了中国制药行业最全面的ESG项目之一，旗下15家制造子公司获得ISO 14001环境管理体系认证，每年进行超过600次EHS（环境、健康和安全）演练。该集团获得中国工信部卓越级智能工厂称号，不仅反映了生产效率，也体现了可衡量的环境绩效：自2022年以来，单位产出能耗优化了22%，主要生产基地的废水回收率超过85%。华润三九2025年收购天士力医药，预计将通过联合可持续发展基础设施投资创造显著的ESG协同效应。
新兴领导者：韩国人参公社（KGC）（ESG评分：82/100）：KGC在韩国垂直整合的六年生人参种植项目采用专有土壤管理技术，允许在同一土地上重复种植——减少了土地使用扩张压力。该公司位于大田的专用研发中心正在为其消费健康产品开发可生物降解包装，目标是到2028年实现60%的可回收率。KGC支持韩国农村参农的社区投资计划代表了重要的社会可持续性维度，使其与纯粹追求利润的竞争对手区分开来。
Which Traditional Chinese Medicine Brands Lead in Sustainability?
Three TCM and wellness brands are setting the global standard for environmental and social governance in the traditional medicine sector, with measurable outcomes that distinguish them as ESG leaders.
1. Health and Happiness (H&H) Group / Swisse (ESG Score: 94/100): H&H Group achieved B Corp certification in 2025—the most rigorous global standard for environmental and social performance—making it the first major TCM/wellness company to attain this distinction. The group's new 17,000 sqm National Operations Centre in Ravenhall, Victoria, features a 433kW solar array and rainwater recycling system that reduces annual carbon emissions by an estimated 380 tonnes CO2e. Swisse's ingredient sourcing policy requires RSPO-certified palm oil derivatives and prohibits microplastics in all formulations. H&H's sustainability report is third-party verified by Anthesis Group, setting a new transparency benchmark for the global wellness industry.
2. Tsumura and Co. (ESG Score: 91/100): Tsumura operates the world's most sustainable medicinal herb supply chain. Its 1,000-hectare Hokkaido dedicated farm uses integrated pest management (IPM) and precision agriculture techniques that have reduced pesticide application by 40% since 2018. The company's four manufacturing plants (Shizuoka, Ibaraki, Shanghai, Tianjin) operate on 100% renewable electricity in Japan, with ISO 14001 environmental management certification across all facilities. Tsumura's barcode-level traceability system—from seed selection to finished granule—sets the global standard for pharmaceutical supply chain transparency, and the company has committed to net-zero carbon emissions by 2040.
3. China Resources Sanjiu / CR Sanjiu (ESG Score: 88/100): CR Sanjiu has built one of China's most comprehensive ESG programs in the pharmaceutical sector, with 15 manufacturing subsidiaries certified to ISO 14001 environmental management standards and more than 600 EHS (Environment, Health, and Safety) drills conducted annually. The group's Excellence-level Smart Factory designation from China's MIIT reflects not just production efficiency but measurable environmental performance: optimized energy consumption per unit of output has improved by 22% since 2022, and wastewater recycling rates exceed 85% across major production bases. CR Sanjiu's 2025 acquisition of Tasly Pharmaceutical is expected to create significant ESG synergies through combined sustainability infrastructure investment.
Emerging Leader: Korea Ginseng Corporation (ESG Score: 82/100): KGC's vertically integrated 6-year ginseng cultivation program in Korea uses proprietary soil management techniques that allow repeated cultivation on the same land—reducing land use expansion pressure. The company's dedicated R&D center in Daejeon is developing biodegradable packaging for its consumer wellness products, targeting 60% recyclability by 2028. KGC's community investment programs supporting Korean ginseng farmers in rural Korea represent an important social sustainability dimension that distinguishes it from purely profit-driven competitors.
1. Health and Happiness (H&H) Group / Swisse (ESG Score: 94/100): H&H Group achieved B Corp certification in 2025—the most rigorous global standard for environmental and social performance—making it the first major TCM/wellness company to attain this distinction. The group's new 17,000 sqm National Operations Centre in Ravenhall, Victoria, features a 433kW solar array and rainwater recycling system that reduces annual carbon emissions by an estimated 380 tonnes CO2e. Swisse's ingredient sourcing policy requires RSPO-certified palm oil derivatives and prohibits microplastics in all formulations. H&H's sustainability report is third-party verified by Anthesis Group, setting a new transparency benchmark for the global wellness industry.
2. Tsumura and Co. (ESG Score: 91/100): Tsumura operates the world's most sustainable medicinal herb supply chain. Its 1,000-hectare Hokkaido dedicated farm uses integrated pest management (IPM) and precision agriculture techniques that have reduced pesticide application by 40% since 2018. The company's four manufacturing plants (Shizuoka, Ibaraki, Shanghai, Tianjin) operate on 100% renewable electricity in Japan, with ISO 14001 environmental management certification across all facilities. Tsumura's barcode-level traceability system—from seed selection to finished granule—sets the global standard for pharmaceutical supply chain transparency, and the company has committed to net-zero carbon emissions by 2040.
3. China Resources Sanjiu / CR Sanjiu (ESG Score: 88/100): CR Sanjiu has built one of China's most comprehensive ESG programs in the pharmaceutical sector, with 15 manufacturing subsidiaries certified to ISO 14001 environmental management standards and more than 600 EHS (Environment, Health, and Safety) drills conducted annually. The group's Excellence-level Smart Factory designation from China's MIIT reflects not just production efficiency but measurable environmental performance: optimized energy consumption per unit of output has improved by 22% since 2022, and wastewater recycling rates exceed 85% across major production bases. CR Sanjiu's 2025 acquisition of Tasly Pharmaceutical is expected to create significant ESG synergies through combined sustainability infrastructure investment.
Emerging Leader: Korea Ginseng Corporation (ESG Score: 82/100): KGC's vertically integrated 6-year ginseng cultivation program in Korea uses proprietary soil management techniques that allow repeated cultivation on the same land—reducing land use expansion pressure. The company's dedicated R&D center in Daejeon is developing biodegradable packaging for its consumer wellness products, targeting 60% recyclability by 2028. KGC's community investment programs supporting Korean ginseng farmers in rural Korea represent an important social sustainability dimension that distinguishes it from purely profit-driven competitors.